Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935709 | 0.85 | FFAR4 (0.46) | FFAR4MTNR1B | |
| SCHEMBL4855749 | 0.84 | FFAR4 (0.41) | FFAR4MTNR1BGPBAR1CYSLTR1ACACB | |
| SCHEMBL755279 | 0.84 | FFAR4 (0.41) | FFAR4MTNR1BGPBAR1CYSLTR1ACACB | |
| SCHEMBL4680033 | 0.80 | MRGPRX4 (0.40) | MTNR1B | |
| SCHEMBL31664429 | 0.79 | SMN1; SMN2 (0.44) | FFAR4GPBAR1CYSLTR1ACACB | |
| SCHEMBL16950678 | 0.78 | NQO1 (0.48) | FFAR4 | |
| SCHEMBL757118 | 0.77 | FFAR4 (0.43) | FFAR4 | |
| SCHEMBL9856358 | 0.77 | SHBG (0.46) | FFAR4GPBAR1CYSLTR1ACACBDHODH | |
| SCHEMBL31550335 | 0.77 | FFAR4 (0.43) | FFAR4MTNR1BGPBAR1CYSLTR1ACACB | |
| SCHEMBL697670 | 0.75 | CHRM2 (0.50) | MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | FFAR4 3909/4885MTNR1B 925/4885GPBAR1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.